A recent study found that while treatment outcomes for a CLL therapy are comparable in clinical trials and the real-world setting, adverse events are increased in the latter. READ MORE
Obinutuzumab may improve survival and lower the risk of worsening disease compared with rituximab in patients with follicular lymphoma.
Research in Review
Single-agent blinatumomab demonstrated antileukemia activity in pediatric patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, according to a study published in the Journal of Clinical Oncology.
Patients with chronic myeloid leukemia and a history of prior malignancies appear to have the same outcomes as patients with no prior malignancies, according to a study published in Cancer.
Researchers may have found a cost-efficient way of examining individual leukemia cells, which could transform treatment strategies and make care more personalized.